Skip to main content

Ublituximab: First Approval

Abstract

Ublituximab (ublituximab-xiiy; BRIUMVI) is a glycoengineered anti-CD20 monoclonal antibody developed by TG Therapeutics, Inc. for the treatment of multiple sclerosis (MS). The mechanism of action of ublituximab involves the depletion of B cells via antibody-dependent cellular cytotoxicity, as B cells have a key role in the pathogenesis of MS. Ublituximab is the first anti-CD20 treatment that is administered twice-yearly as one hour infusions, following the initial doses. In December 2022, ublituximab received its first global approval in the USA for the treatment of adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This article summarizes the milestones in the development of ublituximab leading to this first approval in this indication.

This is a preview of subscription content, access via your institution.

References

  1. Margoni M, Preziosa P, Filippi M, et al. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269(3):1316–34.

    Article  CAS  PubMed  Google Scholar 

  2. TG Therapeutics Inc. TG Therapeutics announces FDA approval of BRIUMVI™ (ublituximab-xiiy) [media release]. 28 Dec 2022. https://ir.tgtherapeutics.com/.

  3. TG Therapeutics Inc. BRIUMVI™ (ublituximab-xiiy): US prescribing information. 2022. https://dailymed.nlm.nih.gov/. Accessed 22 Feb 2023.

  4. TG Therapeutics Inc. TG Therapeutics completes licensing agreement with LFB Biotechnologies for the development of ublituximab [media release]. 2 Mar 2012. http://www.tgtherapeutics.com.

  5. T. G. Therapeutics Inc. TG Therapeutics announces exclusive licensing agreement with Ildong Pharmaceutical Co., Ltd. for development and commercialization of ublituximab (TGTX-1101) in South Korea and Southeast Asia [media release]. 15 Nov 2012.

  6. Bar-Or A, O’Brien SM, Sweeney ML, et al. Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs. 2021;35(9):985–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Alvarez E, Steinman L, Fox E, et al. Reduced disease progression with ublituximab vs teriflunomide in the phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis [abstract no. DMT03 plus presentation]. Int J MS Care. 2022;24(Suppl 1):2.

    Google Scholar 

  8. Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–9.

    Article  CAS  PubMed  Google Scholar 

  9. Lovett-Racke AE, Yang Y, Liu Y, et al. B cell depletion changes the immune cell profile in multiple sclerosis patients: one-year report. J Neuroimmunol. 2021;359: 577676.

    Article  CAS  PubMed  Google Scholar 

  10. Lovett-Racke AE, Gormley M, Liu Y, et al. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019;332:187–97.

    Article  CAS  PubMed  Google Scholar 

  11. Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–14.

    Article  CAS  PubMed  Google Scholar 

  12. Alvarez E, Steinman L, Fox E, et al. Neutralizing antibodies and antidrug antibodies in the ublituximab phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis [abstract no. P103 plus poster]. Mult Scler J. 2022;28(1 Suppl):67.

    Google Scholar 

  13. Steinman L, Alvarez E, Fox E, et al. Ublituximab is associated with significant improvement in the multiple sclerosis functional composite (MSFC): results from the phase 3 ULTIMATE I & II studies [abstract no. P932 plus poster]. Mult Scler J. 2021;27(2):760–1.

    Google Scholar 

  14. Cree B, Fox E, Hartung HP, et al. Disability improvements with ublituximab in relapsing multiple sclerosis (RMS): expanded disability status scale (EDSS), 9-hole peg test (9-HPT), and timed 25-foot walk (T25FW) evaluations from the phase 3 ULTIMATE I and II studies [abstract no. P5-4.009 plus poster]. Neurology. 2022;98(18):963.

    Google Scholar 

  15. Selmaj K, Steinman L, Fox E, et al. Improved quality of life with ublituximab in the ULTIMATE I and II studies in relapsing multiple sclerosis [abstract no. EPO-399 plus poster]. Eur J Neurol. 2022;29(1):634–5.

    Google Scholar 

  16. Alvarez E, Steinman L, Hartung HP, et al. NEDA-4 with ublituximab versus teriflunomide in the ULTIMATE I and II studies in participants with relapsing multiple sclerosis [abstract no. P684 plus poster]. Mult Scler J. 2022;28(3):602–3.

    Google Scholar 

  17. Cree BAC, Fox EJ, Hartung HP, et al. Functional systems scores and expanded disability status scale score evaluations in the ultimate I and II studies of ublituximab versus teriflunomide in participants with relapsing multiple sclerosis [abstract no. P290 plus poster]. Mult Scler J. 2022;28(3):329–30.

    Google Scholar 

  18. Cree B, Fox E, Hartung H, et al. Disability improvements with ublituximab in relapsing multiple sclerosis: pooled post hoc analyses of ULTIMATE I and II [abstract no. EPO-391 plus poster]. Eur J Neurol. 2022;29(Suppl 1):628–9.

    Google Scholar 

  19. Steinman L, Fox EJ, Hartung HP, et al. Disease outcomes with ublituximab in treatment-naive participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis [abstract no. P688 plus poster]. Mult Scler J. 2022;28(3 Suppl):605–6.

    Google Scholar 

  20. Wray S, Steinman L, Hartung HP, et al. Disability changes in the absence of relapse in the phase 3 ULTIMATE I and II studies of ublituximab versus teriflunomide in participants with relapsing multiple sclerosis [abstract no. P295 plus poster]. Mult Scler J. 2022;28(3 Suppl):333–4.

    Google Scholar 

  21. US Food and Drug Administration. 761238Orig1s000: summary review. 2022. https://www.fda.gov/. Accessed 22 Feb 2023.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arnold Lee.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 203 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, A. Ublituximab: First Approval. Drugs 83, 455–459 (2023). https://doi.org/10.1007/s40265-023-01854-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01854-z